EUVIMEDОткрийте EUVIMED
Open access · CC BY-NC-ND 4.0

Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy

Guomin Gu, Chunling Liu, Xiaodan Zhu, Yan Yang, Shuming Song, Yan Zhao, Gang Sun

Journal of Cancer Research and Clinical Oncology · 2024-09-07 · 150 (9)

DOI: 10.1007/s00432-024-05932-x ↗

At a glance

Journal article in Journal of Cancer Research and Clinical Oncology, published online on 2024-09-07. Written by Guomin Gu and 6 co-authors. Institution: Department of Pulmonary Medicine, Affiliated Cancer Hospital of Xinjiang Medical University, No. 789 Suzhou East Street, Xincheng District, Urumqi, X…. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Mutation. Cited 8 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Department of Science and Technology of Xinjiang Uygur Autonomous Region.

РезюмеSubjectsБиблиографски данниCiteRelated studies

Abstract (original language)

PURPOSE: Non-small cell lung cancer (NSCLC) is a highly fatal malignancy. The Kirsten rat sarcoma viral oncogene (KRAS) gene profoundly impacts patient prognosis. This study aims to explore the correlation between KRAS mutation subtypes, clinical data, and the impact of these subtypes on immunotherapy. MATERIALS AND METHODS: Tumor samples from 269 NSCLC patients at the Affiliated Cancer Hospital of Xinjiang Medical University were analyzed. Patients received first- or second-line therapy without targeted therapy. Molecular and clinical data were used to analysis KRAS mutation subtypes and treatment outcomes. RESULTS: KRAS mutations predominantly included G12C, G12D, and G12V subtypes. TP53 had the highest mutation frequency among KRAS mutations, followed by MST1, STK11, and KMT2C. Gender differences were noted among KRAS mutation subtypes, with G12C and G12V mutations prevalent in males, while G12D mutations were less common among males. Smokers exhibited varied KRAS mutation subtypes, with G12C and G12V prevalent in smokers and G12D in nonsmokers. KRAS mutations were mainly in lung adenocarcinoma. TTF-1 and PD-L1 expression differed significantly among KRAS mutations. Patients with G12C and G12V mutations showed higher TMB levels and better immunotherapy outcomes compared to those without KRAS mutations. Conversely, patients with G12D mutations had poorer immunotherapy responses. CONCLUSIONS: KRAS mutation subtypes exhibit distinct clinical and molecular characteristics and varying responses to immunotherapy. G12C and G12V mutations correlate with better immunotherapy outcomes, while G12D mutations are associated with poorer responses.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins p21(ras)Lung NeoplasmsMutationImmunotherapyHumansMaleFemaleMiddle AgedPrognosisChinaAgedAdultAged, 80 and overBiomarkers, Tumor

Author keywords

KRASImmunotherapyMutationNSCLCPrognosis

Substances

Proto-Oncogene Proteins p21(ras)KRAS protein, humanBiomarkers, Tumor

Authors and institutions

  • Department of Pulmonary Medicine, Affiliated Cancer Hospital of Xinjiang Medical University, No. 789 Suzhou East Street, Xincheng District, Urumqi, Xinjiang, 830011, China.
  • Education and Research Management Office, Affiliated Cancer Hospital of Xinjiang Medical University, No. 789 Suzhou East Street, Xincheng District, Urumqi, Xinjiang, 830011, China.
  • Department of Breast and Thyroid Surgery, Affiliated Cancer Hospital of Xinjiang Medical University, No. 789 Suzhou East Street, Xincheng District, Urumqi, Xinjiang, 830011, China. sung853219@126.com.
  • Xinjiang Cancer Center/Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, Xinjiang, 830011, China. sung853219@126.com.

Funding

  • Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region
  • Department of Science and Technology of Xinjiang Uygur Autonomous Region

Cite

APA

Gu, G., Liu, C., Zhu, X., Yang, Y., Song, S., Zhao, Y., & Sun, G. (2024). Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy. Journal of Cancer Research and Clinical Oncology, 150(9). https://doi.org/10.1007/s00432-024-05932-x

Vancouver

Gu G, Liu C, Zhu X, Yang Y, Song S, Zhao Y, et al. Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy. Journal of Cancer Research and Clinical Oncology. 2024;150(9). doi:10.1007/s00432-024-05932-x

BibTeX
@article{Gu2024,
  author = {Gu, Guomin and Liu, Chunling and Zhu, Xiaodan and Yang, Yan and Song, Shuming and Zhao, Yan and Sun, Gang},
  title = {Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  volume = {150},
  number = {9},
  doi = {10.1007/s00432-024-05932-x}
}
Start for free →